These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25867645)

  • 1. Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT.
    Brierley CK; Littlewood TJ; Peniket AJ; Gregg R; Ward J; Clark A; Parker A; Malladi R; Medd P
    Bone Marrow Transplant; 2015 Jul; 50(7):931-8. PubMed ID: 25867645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABO blood group antigen mismatch has an impact on outcome after allogeneic peripheral blood stem cell transplantation.
    Grube M; Wolff D; Ahrens N; Herzberg PY; Herr W; Holler E
    Clin Transplant; 2016 Nov; 30(11):1457-1465. PubMed ID: 27618621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of donor and recipient ABO incompatibility and antibody-associated complications after allogeneic stem cell transplantation with reduced-intensity conditioning.
    Watz E; Remberger M; Ringden O; Lundahl J; Ljungman P; Mattsson J; Wikman A; Uhlin M
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):264-71. PubMed ID: 24274982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is ABO mismatch another risk factor for allogeneic hematopoietic stem cell transplantation in pediatric thalassemic patients?
    Atay D; Erbey F; Akcay A; Ozturk G
    Pediatr Transplant; 2015 Sep; 19(6):645-51. PubMed ID: 26156679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source.
    Blin N; Traineau R; Houssin S; Peffault de Latour R; Petropoulou A; Robin M; Larghero J; Ribaud P; Socié G
    Biol Blood Marrow Transplant; 2010 Sep; 16(9):1315-23. PubMed ID: 20353831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of ABO-incompatible donor on early and late outcome of hematopoietic stem cell transplantation.
    Ozkurt ZN; Yegin ZA; Yenicesu I; Aki SZ; Yagci M; Sucak GT
    Transplant Proc; 2009 Nov; 41(9):3851-8. PubMed ID: 19917400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic peripheral blood stem cell transplantation using reduced-intensity conditioning in an outpatient setting in ABO-incompatible patients: are survival and graft-versus-host disease different?
    Gutiérrez-Aguirre CH; Gómez-De-León A; Alatorre-Ricardo J; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; Mancías-Guerra C; Flores-Jiménez JA; Gómez-Almaguer D
    Transfusion; 2014 May; 54(5):1269-77. PubMed ID: 24898453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning.
    Hefazi M; Litzow M; Hogan W; Gastineau D; Jacob E; Damlaj M; Hashmi S; Al-Kali A; Patnaik MM
    Transfusion; 2016 Feb; 56(2):518-27. PubMed ID: 26446051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation.
    Stussi G; Muntwyler J; Passweg JR; Seebach L; Schanz U; Gmür J; Gratwohl A; Seebach JD
    Bone Marrow Transplant; 2002 Jul; 30(2):87-93. PubMed ID: 12132047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABO blood group barrier in allogeneic bone marrow transplantation revisited.
    Seebach JD; Stussi G; Passweg JR; Loberiza FR; Gajewski JL; Keating A; Goerner M; Rowlings PA; Tiberghien P; Elfenbein GJ; Gale RP; van Rood JJ; Reddy V; Gluckman E; Bolwell BJ; Klumpp TR; Horowitz MM; Ringdén O; Barrett AJ;
    Biol Blood Marrow Transplant; 2005 Dec; 11(12):1006-13. PubMed ID: 16338623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation.
    Kim JG; Sohn SK; Kim DH; Baek JH; Lee KB; Min WS; Kim CC; Lee MH; Lee JJ; Chung IJ; Kim HJ; Lee JW
    Bone Marrow Transplant; 2005 Mar; 35(5):489-95. PubMed ID: 15654350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of ABO blood group incompatibility on the outcomes of allogeneic hematopoietic stem cell transplantation.
    Ciftciler R; Goker H; Buyukasık Y; Karaagac T; Aksu S; Tekin F; Demiroglu H
    Transfus Apher Sci; 2020 Feb; 59(1):102597. PubMed ID: 31311753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning.
    Worel N; Greinix HT; Supper V; Leitner G; Mitterbauer M; Rabitsch W; Fischer G; Rosenmayr A; Höcker P; Kalhs P
    Transfusion; 2007 Aug; 47(8):1494-502. PubMed ID: 17655594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABO incompatible stem cell transplantation in children does not influence outcome.
    Helming AM; Brand A; Wolterbeek R; van Tol MJ; Egeler RM; Ball LM
    Pediatr Blood Cancer; 2007 Sep; 49(3):313-7. PubMed ID: 16960869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consequences of ABO incompatibility in multiple myeloma patients undergoing peripheral blood stem cell transplantation after reduced intensity conditioning.
    Marenchino D; Maddalena L; Balbo R; Avonto I; Menardi G; Prucca M; Perotti L; Mordini N; Peano G
    Blood Transfus; 2011 Jan; 9(1):79-85. PubMed ID: 21084015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of recipient ABH secretor status on outcome in minor ABO-incompatible hematopoietic stem cell transplantation.
    Holbro A; Stern M; Infanti L; O'Meara A; Drexler B; Frey BM; Tiercy JM; Passweg JR; Gassner C; Buser A; Sigle JP
    Transfusion; 2015 Jan; 55(1):64-9. PubMed ID: 24990435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immuno-hematological monitoring after allogeneic stem cell transplantation: a single-center, prospective study of 104 patients.
    La Rocca U; Barberi W; Di Rocco A; Giovannetti G; Neri A; Santilio I; Carmini D; Quattrocchi L; Gozzer M; Bafti MS; Ricci R; Girelli G; Foà R; Iori AP; Coluzzi S
    Blood Transfus; 2022 Sep; 20(5):404-413. PubMed ID: 35543676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML.
    Malladi RK; Peniket AJ; Littlewood TJ; Towlson KE; Pearce R; Yin J; Cavenagh JD; Craddock C; Orchard KH; Olavarria E; McQuaker G; Collin M; Marks DI;
    Bone Marrow Transplant; 2009 May; 43(9):709-15. PubMed ID: 19029965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABO, alemtuzumab and allogeneic transplantation.
    Cooling L
    Bone Marrow Transplant; 2015 Jul; 50(7):881-3. PubMed ID: 25893459
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of ABO-Incompatibility on Outcome of Allogeneic Hematopoietic Stem Cell Transplantation].
    Yang BB; Gan YF; Chen P; Chen Y; Yu K
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):535-540. PubMed ID: 28446307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.